DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience is a San Diego-based biotech company focused on therapies for obesity and metabolic diseases [2]. - On October 6, 2025, Skye announced that its Phase 2a CBeyond study of nimacimab did not meet its primary weight-loss endpoint compared to placebo, resulting in a 60% drop in share price, from $4.75 to $1.90 [4].